Marco Lobba
Co-Founder & Chief Executive Officer CatenaBio
Seminars
Tuesday 13th October 2026
Leveraging Site-Selective Conjugation to Enable New Modalities & Groundbreaking Dual Payload ADCs With Superior Characteristics & Activity
3:30 pm
- Introducing the CysTyr Platform and design parameters required for a successful dual payload asset
- Demonstrating significantly superior activity for dual payload ADCs versus leading ADCs in CDX and PDX models
- Outlining CysTyr superior manufacturing resulting in unprecedented product purity and homogeneity with tunable DAR
- Unveiling first report on NHP toxicity trial for CATB-101 and significant improvements in therapeutic index versus leading ADCs
